RBBP4 and hepatocellular carcinoma: The blocking SALL4 physical interaction with RBBp4 (a member of the NuRD complex) through a peptide has been proved in HCC [23] and can give an essential pharmacological approach to treating trastuzumab-acquired resistance in BC patients.